Amarantus and Brewer Sports Announce #C4CT Summit Morning Keynote Presentation by Congressman Chaka Fattah
June 25 2014 - 6:30AM
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS) and Brewer Sports
International (BSI), today announced that Congressman Chaka Fattah
will be delivering the morning keynote address at the #C4CT
Concussion Awareness Summit focused on Traumatic Brain
Injury-induced Alzheimer's disease at the United Nations on July
31st, 2014. Congressman Fattah will address the Summit regarding
policy initiatives currently underway to improve funding for Brain
research.
"It is an honor to take part in next month's Summit and help
advance America's commitment to brain research, especially as it
relates to traumatic brain injury (TBI). The Fattah Neuroscience
Initiative is working to leverage the resources within government,
while fostering collaborations and cooperation with partners around
the globe, to expand our neuroscience capabilities as we seek cures
and treatments for Alzheimer's and other brain disease,"
Congressman Fattah said. "The #C4CT Summit will be a unique
opportunity for stakeholders to engage in a necessary dialogue on
how to better understand and address the long-term impacts of
TBI."
Congressman Chaka Fattah is serving in his 10th term in the U.
S. House of Representatives, where he is a senior member of the
House Appropriations Committee and the leading Congressional
advocate for neuroscience. In 2011 Fattah created the Fattah
Neuroscience Initiative and through his leadership on the
Appropriations Committee, directed the Office of Science and
Technology Policy (OSTP) to establish an Interagency Working Group
on Neuroscience (IWGN). The Fattah Neuroscience Initiative is
credited as an impetus for the White House BRAIN initiative and the
Congressman has been recognized by President Obama for his
leadership on the issues of brain research.
The Fattah Neuroscience Initiative is a non-incremental policy
initiative designed to make major progress in understanding the
human brain by intensifying, in a collaborative fashion, federal
research efforts across brain disease, disorder, injury, cognition
and development. The initiative aims to coordinate Federal research
across agencies and draw upon public private partnerships and the
world of academia. This collaboration is significant both in its
interdisciplinary nature and the precedence it stands to set in
addressing broad national priorities. Congressman Fattah is also
partnering with the American Association for the Advancement of
Science (AAAS) to host a series of Congressional briefings
educating Members of Congress and their staff about current
neuroscience research. Topics presented thus far have included
infant brain development, traumatic brain injury, and mental
illness in young adults.
To register, become a partner, or for additional information,
please visit www.c4ctsummit.com. For further questions, please
contact Lindsay Lommel at lindsay.lommel@thebrewergroup.com.
For sponsorship information please visit:
http://www.c4ctsummit.com/sponsorship-opportunities/.
About Amarantus BioScience Holdings, Inc.
Amarantus BioScience Holdings (AMBS) is a biotechnology company
developing treatments and diagnostics for diseases associated with
neurodegeneration and protein misfolding-related apoptosis. AMBS
has licensed Eltoprazine ("Eltoprazine"), a phase 2b ready
indication for Parkinson's Levodopa induced dyskinesia and Adult
ADHD. AMBS has an exclusive worldwide license to the Lymphocyte
Proliferation test ("LymPro Test(R)") for Alzheimer's disease and
owns the intellectual property rights to a therapeutic protein
known as Mesencephalic-Astrocyte-derived Neurotrophic Factor
("MANF") and is developing MANF-based products as treatments for
brain disorders. AMBS also owns intellectual property for the
diagnosis of Parkinson's disease ("NuroPro") and the discovery of
neurotrophic factors ("PhenoGuard"). Amarantus operations are
located at Janssen Labs @QB3 in San Francisco, CA. For further
information please visit www.Amarantus.com, or connect with the
Company on Facebook, LinkedIn, Twitter and Google+.
About Brewer Sports International
Brewer Sports International (BSI) is a multi-faceted sports
advisory firm within The Brewer Group Companies with a focus on the
business of sports, wellness and media for professional athletes,
sports agencies, public and private corporations and various
partners including international organizations, governments and
NGOs. Jack Brewer, five-year National Football League (NFL) veteran
and former three-team captain, launched BSI in Minneapolis and
expanded to New York, Dallas, Miami, Beijing and Malawi. BSI offers
a unique financial services platform to professional athletes and
sports agencies, as well as high-net-worth individuals and
businesses related to professional sports. BSI takes pride in
enabling its clients to capitalize on the endless opportunities
presented through sport. For more information, please visit
www.brewersports.com or follow them on Facebook, Twitter and
LinkedIn.
About #C4CT
The Coalition for Concussion Treatment (#C4CT) was founded in
2012 by former NFL player Jack Brewer, CEO of Brewer Sports
International and Gerald Commissiong, President and CEO at
Amarantus BioScience Holdings, Inc. with the goal of bringing
together those who are directly affected by TBI-induced
neurodegenerative diseases with world class researchers, scientists
and industry leaders whom are actively working towards identifying
and developing innovative TBI treatment opportunities. #C4CT serves
as a platform to spread awareness about concussions and the severe
effects of Traumatic Brain Injury (TBI). Through a global campaign
uniting people who are passionate about the cause, #C4CT fosters
the critical discussions and partnerships needed to enhance
research, treatment efforts and prevention.
CONTACT: Amarantus Bioscience Holdings, Inc.:
Aimee Boutcher, Investor Relations
408.737.2734 x 101
ir@amarantus.com
Brewer Sports International:
Kristi Hofacker, Interactive Marketing and Media Manager
651.247.4460
kristi.hofacker@thebrewergroup.com
Amarantus Bioscience (CE) (USOTC:AMBS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Amarantus Bioscience (CE) (USOTC:AMBS)
Historical Stock Chart
From Apr 2023 to Apr 2024